# Teva Pharmaceutical Industries Ltd.

> Israeli pharmaceutical company

**Wikidata**: [Q898750](https://www.wikidata.org/wiki/Q898750)  
**Wikipedia**: [English](https://en.wikipedia.org/wiki/Teva_Pharmaceuticals)  
**Source**: https://4ort.xyz/entity/teva-pharmaceutical-industries-ltd

## Summary
Teva Pharmaceutical Industries Ltd. is a leading Israeli pharmaceutical company founded in 1901, known for developing, producing, and marketing generic drugs and specialty medications. As one of the world's largest generic pharmaceutical manufacturers, Teva plays a critical role in providing affordable medications globally. Headquartered in Tel Aviv, Israel, the company operates internationally with subsidiaries such as Ratiopharm and Cephalon.

## Key Facts
- **Founded**: 1901 (as Assia) and formally established in 1944.
- **Headquarters**: Tel Aviv, Israel, with additional locations in Petah Tikva.
- **Industry**: Pharmaceutical, specifically generic drugs and specialty medications.
- **Key Products**: Generic drugs, including treatments for conditions like multiple sclerosis, respiratory diseases, and pain management.
- **Subsidiaries**: Ratiopharm, Cephalon, and others, contributing to its global reach.
- **Employees**: Approximately 43,000 globally as of recent data.
- **Stock Exchanges**: Listed on the Tel Aviv Stock Exchange (TASE: TEVA) and New York Stock Exchange (NYSE: TEVA).
- **Founders**: Dr. Franz Hausner, with significant contributions from Günther Friedländer.
- **Ownership**: Publicly traded with institutional investors such as Berkshire Hathaway, BlackRock, and Wellington Management Company.
- **Revenue**: Generated through a diverse portfolio of generic and specialty pharmaceuticals.
- **Notable Acquisitions**: Acquired Cephalon in 2011 and Allergan's generic business in 2016.

## FAQs
**What is Teva Pharmaceutical Industries Ltd. known for?**
Teva is renowned for being one of the world's largest generic drug manufacturers, providing affordable medications globally, and developing specialty pharmaceuticals for conditions like multiple sclerosis.

**When and where was Teva founded?**
Teva was founded in 1901 in Jerusalem, initially as Assia, and was formally established in its current form in 1944 in Tel Aviv, Israel.

**What are Teva's primary products?**
Teva's primary products include generic drugs and specialty medications, such as Copaxone for multiple sclerosis, and treatments for respiratory diseases and pain management.

**Who are the key investors in Teva?**
Major institutional investors include Berkshire Hathaway, BlackRock, and Wellington Management Company, reflecting its status as a publicly traded company.

**What significant acquisitions has Teva made?**
Notable acquisitions include Cephalon in 2011 for $6.8 billion and Allergan's generic business in 2016 for $40.5 billion, expanding its global footprint and product portfolio.

## Why It Matters
Teva Pharmaceutical Industries Ltd. is pivotal in the global healthcare ecosystem, addressing the need for affordable medications through its generic drug portfolio. Its specialty pharmaceuticals, such as Copaxone, have transformed treatment landscapes for debilitating conditions. As a major player in the pharmaceutical industry, Teva influences drug pricing, accessibility, and innovation, particularly in the generic drug sector. Its extensive research and development efforts contribute to medical advancements, while its global operations support healthcare systems worldwide.

## Notable For
- **Global Generic Drug Leadership**: Teva is one of the world's largest generic pharmaceutical companies, significantly impacting drug affordability and accessibility.
- **Specialty Medications**: Developed and marketed Copaxone, a breakthrough treatment for multiple sclerosis, demonstrating its commitment to addressing critical healthcare needs.
- **Strategic Acquisitions**: Expanded its portfolio and global reach through acquisitions like Cephalon and Allergan's generic business, enhancing its market position.
- **Israeli Economic Impact**: As a major Israeli corporation, Teva contributes substantially to the country's economy and technological innovation.
- **Diverse Product Portfolio**: Offers a wide range of medications, from generics to specialty drugs, catering to various therapeutic areas.

## Body

### History and Founding
Teva Pharmaceutical Industries Ltd. traces its origins to 1901 when Dr. Franz Hausner established Assia, a small pharmaceutical company in Jerusalem. The company evolved through mergers, notably with Zori in 1960, and was formally restructured in 1944. Günther Friedländer, an Israeli pharmacist, played a crucial role in its early development. Over the decades, Teva expanded globally, driven by strategic acquisitions and a focus on generic drug production.

### Global Operations and Subsidiaries
Headquartered in Tel Aviv, Israel, Teva operates internationally with key subsidiaries such as Ratiopharm in Germany and Cephalon in the United States. These subsidiaries enhance Teva's global market presence, enabling the distribution of its products across continents. The company's manufacturing and research facilities are located in multiple countries, supporting its large-scale production capabilities.

### Product Portfolio and Innovation
Teva's product portfolio is divided into generic drugs and specialty medications. Its generic division offers affordable alternatives to brand-name drugs, covering a broad spectrum of therapeutic areas. The specialty division focuses on innovative treatments, including Copaxone for multiple sclerosis and Austedo for movement disorders. The company invests heavily in research and development, with notable contributions to neurology and respiratory medicine.

### Financial and Ownership Structure
As a publicly traded company, Teva is listed on the Tel Aviv Stock Exchange (TASE: TEVA) and the New York Stock Exchange (NYSE: TEVA). Institutional investors such as Berkshire Hathaway, BlackRock, and Wellington Management Company hold significant stakes. The company's revenue streams are diversified across its generic and specialty segments, with a global customer base.

### Challenges and Controversies
Teva has faced challenges, including debt management following major acquisitions and pricing pressures in the generic drug market. The company has also encountered regulatory scrutiny and legal disputes, particularly regarding Copaxone's patent protection and pricing strategies. These challenges have prompted strategic restructuring efforts to maintain competitiveness.

### Corporate Social Responsibility
Teva engages in corporate social responsibility initiatives, focusing on healthcare access, environmental sustainability, and community development. The company collaborates with global health organizations to improve medication availability in underserved regions, aligning with its mission to enhance healthcare outcomes worldwide.

### Technological and Manufacturing Capabilities
Teva leverages advanced manufacturing technologies to ensure high-quality production standards. Its facilities adhere to strict regulatory requirements, enabling the consistent supply of medications. The company's investment in technology supports efficient production processes and innovation in drug delivery systems.

### Market Position and Competitors
Teva maintains a leading position in the global generic pharmaceutical market, competing with companies such as Mylan and Pfizer's Upjohn division. Its specialty medications face competition from both generic and branded drug manufacturers. The company's strategy focuses on leveraging its scale, portfolio breadth, and innovation to sustain its market share.

### Future Directions
Teva continues to navigate the evolving pharmaceutical landscape, prioritizing debt reduction, operational efficiency, and strategic investments in research and development. The company aims to capitalize on growth opportunities in emerging markets and expand its specialty medication pipeline, ensuring long-term sustainability and relevance in the global healthcare sector.

## References

1. Global LEI Index
2. Tel Aviv Stock Exchange site
3. [Source](https://www.tevapharm.com/news-and-media/latest-news/teva-announces-appointment-of-richard-francis-as-president-and-ceo/)
4. GRID Release 2017-01-10
5. Virtual International Authority File
6. BnF authorities
7. Polygon.io
8. ROR release v1.19
9. [OpenCorporates](https://opencorporates.com/companies/il/520013954)
10. Freebase Data Dumps. 2013
11. Google Knowledge Graph
12. GRID Release 2015-12-14
13. GRID Release 2016-12-06
14. Quora
15. [Source](https://golden.com/wiki/Teva_Pharmaceutical_Industries-BMR38G)
16. YouTube API
17. Wikirate